
THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon, it was announced today.
The standalone company is expected to generate annual revenues of approximately £10 billion, rising by between 4% and 6% per year, through sales of over-the-counter power brands including Sensodyne, Panadol and Nicorette.